Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer

Cancer

Volumn 121, Issue 13, 2015, Pages 2108-2120

  Walker, Joan L ^a   Powell, C Bethan ^b   Chen, Lee May ^c   Carter, Jeanne ^d   Bae Jump, Victoria L ^e   Parker, Lynn P ^f   Borowsky, Mark E ^g   Gibb, Randall K ^h  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Norton Healthcare   (United States)

^g HELEN F GRAHAM CANCER CENTER   (United States)

^h BILLINGS CLINIC   (United States)

Author keywords

BRCA; carriers; Cascade genetic testing; fallopian tube; genetic testing; mastectomy; oral contraceptives; ovarian cancer; prevention; risk reducing bilateral salpingo oophorectomy (BSO); salpingectomy

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

CANCER GRADING; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; DRUG USE; EVIDENCE BASED MEDICINE; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GYNECOLOGY; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; ONCOLOGY; OVARY CANCER; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK REDUCTION; SALPINGECTOMY; SALPINGOOOPHORECTOMY; UTERINE TUBE STERILIZATION; FALLOPIAN TUBE; FEMALE; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; RISK FACTOR;

FALLOPIAN TUBES; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84931068694     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29321     Document Type: Review

References (158)

1. American Cancer Society. Ovarian cancer. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics. Accessed March 21, 2013.
2. Goff BA, Lowe KA, Kane JC, Robertson MD, Gaul MA, Andersen MR,. Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol. 2012; 124: 230-235.
3. Buys SS, Partridge E, Black A, et al., Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011; 305: 2295-2303.
4. Goff BA,. Ovarian cancer: screening and early detection. Obstet Gynecol Clin North Am. 2012; 39: 183-194.
5. Goff B,. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012; 55: 36-42.
6. Andersen MR, Goff BA, Lowe KA, et al., Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008; 113: 484-489.
7. Gilbert L, Basso O, Sampalis J, et al., Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012; 13: 285-291.
8. Andersen MR, Goff BA, Lowe KA, et al., Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010; 116: 378-383.
9. Goff BA, Matthews B, Andrilla CH, et al., How are symptoms of ovarian cancer managed? A study of primary care physicians. Cancer. 2011; 117: 4414-4423.
10. Cibula D, Widschwendter M, Majek O, Dusek L,. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update. 2011; 17: 55-67.
11. Rice MS, Murphy MA, Tworoger SS,. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012; 5: 13.
12. Lu KH, Skates S, Hernandez MA, et al., A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013; 119: 3451-3461.
13. Havrilesky LJ, Moorman PG, Lowery WJ, et al., Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 139-147.
14. Guillem JG, Wood WC, Moley JF, et al., ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006; 24: 4642-4660.
15. Levine DA, Gemignani ML,. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Oncology (Williston Park). 2003; 17: 932-941.
16. Kurman RJ, Shih IM,. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011; 42: 918-931.
17. Li J, Abushahin N, Pang S, et al., Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol. 2011; 106: 1-12.
18. Vang R, Shih IM, Kurman RJ,. Ovarian low-grade and high-grade serous carcinoma-pathogenesis, clinicopathologic and molecular biologic features and diagnostic problems. Adv Anat Pathol. 2009; 16: 267-282.
19. Vercellini P, Crosignani P, Somigliana E, et al., The 'incessant menstruation' hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod. 2011; 26: 2262-2273.
20. Kurman RJ, Shih IM,. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34: 433-443.
21. Medeiros F, Muto MG, Lee Y, et al., The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006; 30: 230-236.
22. Kindelberger DW, Lee Y, Miron A, et al., Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007; 31: 161-169.
23. Bowtell DDL,. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010; 10: 803-808.
24. Brown PO, Palmer C,. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009; 6: e1000114.
25. Carlson JW, Miron A, Jarboe EA, et al., Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008; 26: 4160-4165.
26. Crum CP, Drapkin R, Kindelberger DW, Medeiros F, Miron A, Lee Y,. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007; 5: 35-44.
27. Crum CP, Drapkin R, Miron A, et al., The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007; 19: 3-9.
28. Karst AM, Levanon K, Drapkin R,. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A. 2011; 108: 7547-7552.
29. Lee Y, Miron A, Drapkin R, et al., A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-35.
30. Quick CM, Ning G, Bijron J, et al., PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Mod Pathol. 2012; 25: 449-455.
31. Salvador S, Gilks CB, Kobel M, Huntsman D, Rosen B, Miller D,. The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009; 19: 58-64.
32. Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP,. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009; 22: 985-988.
33. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H,. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009; 22: 1133-1138.
34. Dietl J, Wischhusen J, Hausler SFM,. The post-reproductive fallopian tube: better removed? Hum Reprod. 2011; 26: 2918-2924.
35. Dietl J, Wischhusen J,. The forgotten fallopian tube. Nat Rev Cancer. 2011; 11: 227.
36. Greene MH, Mai PL, Schwartz PE,. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011; 204: 19-16.
37. LeBlanc E, Narducci F, Farre, et al., Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol. 2011; 121: 472-476.
38. Morelli M, Venturella R, Mocciaro R, et al., Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013; 129: 448-451.
39. Sezik M, Ozkaya O, Demir F, Sezik HT, Kaya H,. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. J Obstet Gynaecol Res. 2007; 33: 863-869.
40. Yi Q, Ling S, Chen K, He W, Li L, Yi C,. Evaluation of the clinical value of simultaneous hysterectomy and bilateral salpingectomy in perimenopausal women [in Chinese]. Zhonghau Fu Chan Ke Za Zhi. 2012; 47: 110-114.
41. Cibula D, Zikan M, Dusek L, Majek O,. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011; 11: 1197-1207.
42. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G,. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371: 303-314.
43. Iodice S, Barile M, Rotmensz N, et al., Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 2010; 46: 2275-2284.
44. Kwon JS, Tinker A, Pansegrau G, et al., Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013; 121: 14-24.
45. Cibula D, Widschwendter M, Zikan M, Dusek L,. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. 2011; 90: 559-563.
46. McAlpine J, Hanley G, Woo M, et al., Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014; 210: 471-473.
47. Saad AF, Hu W, Sood AK,. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010; 1: 277-290.
48. Munksgaard PS, Blaakaer J,. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012; 124: 164-169.
49. Gilks CB,. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol. 2010;2010: 740968.
50. Nik NN, Vang R, Shih I, Kurman RJ,. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol. 2014; 9: 27-45.
51. Lim D, Oliva E,. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45: 229-242.
52. Pearce CL, Templeman C, Rossing MA, et al., Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012; 13: 385-394.
53. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med. 2010; 363: 1532-1543.
54. Ogawa S, Kaku T, Amada S, et al., Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000; 77: 298-304.
55. Prefumo F, Todeschini F, Fulcheri E, Venturini PL,. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol. 2002; 84: 280-284.
56. LaGrenade A, Silverberg SG,. Ovarian tumors associated with atypical endometriosis. Hum Pathol. 1988; 19: 1080-1084.
57. Moll UM, Chumas JC, Chalas E, Mann WJ,. Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol. 1990; 75 (3 pt 2): 537-539.
58. ACOG practice bulletin no. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010; 115: 206-218.
59. Sainz de la Cuesta R, Eichhorn JH, Rice LW, Fuller AF Jr, Nikrui N, Goff BA,. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996; 60: 238-244.
60. Bowen NJ, Logani S, Dickerson EB, et al., Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007; 104: 331-337.
61. Riopel MA, Ronnett BM, Kurman RJ,. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999; 23: 617-635.
62. Crum CP,. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Biol. 2009; 3: 165-170.
63. Tone AA, Begley H, Sharma M, et al., Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res. 2008; 14: 4067-4078.
64. Walsh T, Casadei S, Lee MK, et al., Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108: 18032-18037.
65. Pennington KP, Swisher EM,. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol. 2012; 124: 347-353.
66. Norquist BM, Garcia RL, Allison KH, et al., The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010; 116: 5261-5271.
67. Hu CY, Taymor ML, Hertig AT,. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol. 1950; 59: 58-67.
68. Zweemer RP, van Diest PJ, Verheijen RHM, et al., Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol. 2000; 76: 45-50.
69. Powell CB, Kenley E, Chen L, et al., Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005; 23: 127-132.
70. Leeper K, Garcia R, Swisher E, Goff BA, Greer B, Paley P,. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002; 87: 52-56.
71. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ,. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100: 58-64.
72. Callahan MJ, Crum CP, Medeiros F, et al., Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25: 3985-3990.
73. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM,. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006; 194: 1702-1709.
74. Powell CB, Chen LM, McLennan J, et al., Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011; 21: 846-851.
75. Sherman-Baust CA, Kuhn E, Valle BL, et al., A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014; 233: 228-237.
76. Yates MS, Meyer LA, Deavers MT, et al., Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011; 4: 463-470.
77. Piek JM, van Diest PJ, Zweemer RP, et al., Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195: 451-456.
78. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ,. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003; 90: 491.
79. Marquez RT, Baggerly KA, Patterson AP, et al., Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005; 11: 6116-6126.
80. Powell CB,. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later. Gynecol Oncol. 2014; 132: 261-263.
81. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih M,. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2015; 34: 829-836.
82. Kuhn E, Kurman RJ, Shih L,. Ovarian cancer is an imported disease: fact or fiction? Curr Obstet Gynecol Rep. 2012; 1: 1-9.
83. Blank SV,. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2011; 117 (2 pt 1): 404.
84. Berek JS, Bast RCJ,. Ovarian cancer. In:, Kufe DW, Bast RC Jr, Hait WM, eds. Cancer Medicine. Hamilton, Canada: BC Dekker; 2006: 1543-1568.
85. Olsen CM, Nagle CM, Whiteman DC, et al., Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013; 20: 251-262.
86. Dumesic DA, Lobo RA,. Cancer risk and PCOS. Steroids. 2013; 78: 782-785.
87. Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E,; Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer. 2004; 90: 1386-1391.
88. Ness RB, Grisso JA, Klapper J, et al., Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000; 152: 233-241.
89. Narod SA, Risch H, Moslehi R, et al., Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998; 339: 424-428.
90. Shao R, Nutu M, Weijdegard B, et al., Clomiphene citrate causes aberrant tubal apoptosis and estrogen receptor activation in rat fallopian tube: implications for tubal ectopic pregnancy. Biol Reprod. 2009; 80: 1262-1271.
91. George SH, Greenaway J, Milea A, et al., Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol. 2011; 225: 106-117.
92. George SH, Milea A, Shaw PA,. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. Clin Cancer Res. 2012; 18: 6199-6207.
93. Gierisch JM, Coeytaux RR, Peragallo UR, et al., Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1931-1943.
94. Peragallo UR, Coeytaux RR, McBroom AJ, et al., Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 380-389.
95. Grenader T, Peretz T, Lifchitz M, Shavit L,. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast. 2005; 14: 264-268.
96. Moorman PG, Havrilesky LJ, Gierisch JM, et al., Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31: 4188-4198.
97. McLaughlin JR, Risch HA, Lubinski J, et al., Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007; 8: 26-34.
98. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH,. Tubal ligation and risk of ovarian cancer. Lancet. 2001; 358: 844.
99. Green A, Purdie D, Bain C, et al., Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer. 1997; 71: 948-951.
100. Rosenblatt KA, Thomas DB,. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996; 5: 933-935.
101. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH,. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65,000 sterilized women. Int J Epidemiol. 2004; 33: 596-602.
102. Irwin KL, Weiss NS, Lee NC, Peterson HB,. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol. 1991; 134: 362-369.
103. Antoniou AC, Rookus M, Andrieu N, et al., Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2009; 18: 601-610.
104. Narod SA, Sun P, Ghadirian P, et al., Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001; 357: 1467-1470.
105. McGuire V, Felberg A, Mills M, et al., Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004; 160: 613-618.
106. Sieh W, Salvador S, McGuire V, et al., Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2013; 42: 579-589.
107. Vicus D, Finch A, Rosen B, et al., Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol. 2010; 118: 155-159.
108. Kauff ND, Barakat RR,. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007; 25: 2921-2927.
109. Domchek SM, Friebel TM, Singer CF, et al., Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304: 967-975.
110. Domchek SM, Friebel TM, Neuhausen SL, et al., Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006; 7: 223-229.
111. Antoniou AC, Pharoah PD, Narod S, et al., Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
112. Eisen A, Lubinski J, Klijn J, et al., Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-controlled study. J Clin Oncol. 2005; 23: 7491-7496.
113. Metcalfe KA, Kim-Sing C, Ghadirian P, Sun P, Narod SA,. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. Clin Genet. 2014; 85: 21-30.
114. Semple J, Metcalfe KA, Lynch HT, et al., International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Ann Surg Oncol. 2013; 20: 3817-3822.
115. Sigal B, Munoz D, Kurian A, Plevritis S,. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1066-1077.
116. Kenkhuis MJ, de Bock GH, Elferink PO, et al., Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas. 2010; 66: 310-314.
117. Finch A, Metcalfe KA, Chiang J, et al., The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology. 2013; 22: 212-219.
118. Robson M, Hensley M, Barakat R, et al., Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 2003; 89: 281-287.
119. Elit L, Esplen MJ, Butler K, Narod S,. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer. 2001; 1: 149-156.
120. Madalinska JB, Hollenstein J, Bleiker E, et al., Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005; 23: 6890-6898.
121. Finch A, Metcalfe KA, Chiang JK, et al., The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol. 2011; 121: 163-168.
122. Finch A, Narod SA,. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas. 2011; 70: 261-265.
123. Benshushan A, Rojansky N, Chaviv M, et al., Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric. 2009; 12: 404-409.
124. van Oostrom I, Meijers-Heijboer H, Lodder LN, et al., Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003; 21: 3867-3874.
125. Hallowell N, Baylock B, Heiniger L, et al., Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery. Fam Cancer. 2012; 11: 215-224.
126. Parker WH, Feskanich D, Broder MS, et al., Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol. 2013; 121: 709-716.
127. Parker WH,. Bilateral oophorectomy versus ovarian conservation: effects on long-term women's health. J Minim Invasive Gynecol. 2010; 17: 161-166.
128. Cohen JV, Chiel L, Boghossian L, et al., Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer. 2012; 11: 69-75.
129. Michelsen TM, Dorum A, Trope CG, Fossa SD, Dahl AA,. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. Int J Gynecol Cancer. 2009; 19: 1029-1036.
130. Michelsen TM, Dorum A, Cvancarova M, Liavaag AH, Dahl AA,. Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample. Gynecol Obstet Invest. 2013; 75: 61-67.
131. Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A,. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer. 2010; 20: 233-239.
132. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III,. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006; 7: 821-828.
133. Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A,. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer. 2009; 45: 82-89.
134. Melton LJ III, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL,. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003; 18: 900-905.
135. Madalinska JB, van Beurden M, Bleiker EM, et al., The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol. 2006; 24: 3576-3582.
136. Somboonporn W, Panna S, Temtanakitpaisan T, Kaewrudee S, Soontrapa S,. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause. 2011; 18: 1060-1066.
137. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E,. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014; 124 (2 pt 1): 292-299.
138. Marchina E, Fontana MG, Speziani M, et al., BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management. Oncol Rep. 2010; 24: 1661-1667.
139. Kauff ND, Satagopan JM, Robson ME, et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 1609-1615.
140. Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A,. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer. 2013; 23: 431-436.
141. Meyer LA, Anderson ME, Lacour RA, et al., Evaluating women with ovarian cancer for 351 BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010; 115: 945-952.
142. Myriad Genetics. Welcome Myriad Genetics: innovating today to ensure growth tomorrow. http://shareholder.com/downloads/MYGN/2784875405x0x661835/b6aec217-4afc-be8e-d0a36414ce91/AnalystDay-Presentation-FINAL.pdf. Accessed February 27, 2015.
143. Lancaster JM, Powell CB, Chen L, Richardson DL,; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015; 136: 3-7.
144. National Comprehensive Cancer Network. NCCN guidelines for detection, prevention, & risk reduction: genetic/familial high-risk assessment: breast and ovarian. http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Accessed November 1, 2014.
145. Morse AN, Schroeder CB, Magrina JF, Webb MJ, Wollan PC, Yawn BP,. The risk of hydrosalpinx formation and adnexectomy following tubal ligation and subsequent hysterectomy: a historical cohort study. Am J Obstet Gynecol. 2006; 194: 1273-1276.
146. Dar P, Sachs GS, Strassburger D, Bukovsky I, Arieli S,. Ovarian function before and after salpingectomy in artificial reproductive technology patients. Hum Reprod. 2000; 15: 142-144.
147. Strandell A, Lindhard A, Waldenstrom U, Thorburn J,. Prophylactic salpingectomy does not impair the ovarian response in IVF treatment. Hum Reprod. 2001; 16: 1135-1139.
148. Chan CCW, Ng EHY, Li CF, Ho PC,. Impaired ovarian blood flow and reduced antral follicle count following laparoscopic salpingectomy for ectopic pregnancy. Hum Reprod. 2003; 18: 2175-2180.
149. Gelbaya TA, Nardo LG, Fitzgerald CT, Horne G, Brison DR, Lieberman BA,. Ovarian response to gonadotropins after laparoscopic salpingectomy or the division of fallopian tubes for hydrosalpinges. Fertil Steril. 2006; 85: 1464-1468.
150. Findley AD, Siedhoff MT, Hobbs KA, et al., Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril. 2013; 100: 1704-1708.
151. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH,. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014; 133: 283-286.
152. Lam A, Secord S, Butler K, et al., A breast reconstruction needs assessment: how does self-efficacy affect information access and preferences? Can J Plast Surg. 2012; 20: 37-42.
153. Visvanathan K, Hurley P, Bantug E, et al., Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31: 2942-2962.
154. Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ,. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013; 70: 435-437.
155. Rebbeck TR, Kauff ND, Domchek SM,. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101: 80-87.
156. Greene MH, Piedmonte M, Alberts D, et al., A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008; 17: 594-604.
157. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez G,. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002; 94: 32-38.
158. Modan B, Hartge P, Hirsh-Yechezkel G, et al., Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 235-240.